Yahoo!   My Yahoo!   Mail  
Search   
Sign In
New User? Sign Up
Home > Investing > ARYX > Summary

ARYx Therapeutics, Inc.
(ARYX)

2.95USD   Up0.02 (0.68%)   
At 2:30AM IST
 ARYx Therapeutics, Inc. (NGM:ARYX) Delayed quote data 
[Chart]
1d  5d  3m  6m  1y  2y  5y 
Last Trade: 2.95USD
Trade Time:2:30AM IST
Change:Up0.02 (0.68%)
Prev Close:2.93
Open:2.98
Bid:2.02 x 100
Ask:3.56 x 100
1y Target Est:6.38
Day's Range:2.93 - 3.03
52wk Range:1.90 - 6.32
Volume:42,778
Avg Vol (3m):76,068.3
Market Cap:81.38M
P/E (ttm):N/A
EPS (ttm):-1.54
Div & Yield:N/A (N/A%)
Add ARYX to Portfolio   Download Data

HEADLINES

 
•Aryx gets FDA guidance on blood clot drug that failed trial - bizjournals.com  - Tue, Jan 5
•ARYX THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits - EDGAR Online  - Tue, Jan 5
•ARYx Therapeutics Receives Guidance on Anticoagulant Agent Tecarfarin - Business Wire  - Tue, Jan 5
•ARYX THERAPEUTICS, INC. Financials - EDGAR Online Financials  - Wed, Nov 18
•Results From Phase 2b Study on Atrial Fibrillation Agent Reviewed at American Heart Association - Business Wire  - Wed, Nov 18
•New Star Analyst Rankings for ARYx Therapeutics, Inc. - StarMine  - Sun, Nov 15
•ARYX THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report - EDGAR Online  - Fri, Nov 13
•Aryx Therapeutics reports $8.2M loss - bizjournals.com  - Thu, Nov 12
•ARYx Therapeutics Reports Third Quarter 2009 Results - Business Wire  - Thu, Nov 12
•Q3 2009 ARYx Therapeutics Earnings Release - Time Not Supplied - CCBN  - Thu, Nov 12
» More Headlines for ARYX...

ANALYST

 
EPS Est (next year) (Dec-09) :-1.20
EPS Est (in 2 years) (Dec-10) :-0.27
Avg Rec (current)*:1.3
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
» Analyst Opinion» Estimates

BUSINESS SUMMARY

 
ARYx Therapeutics, Inc., a biopharmaceutical company, focuses on developing a portfolio of product candidates designed to eliminate known safety issues associated with commercial drugs using its RetroMetabolic Drug Design technology.

» Full Company Profile